Brendan Christopher Visser
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Brendan Christopher Visser has a total of 198 co-authors. Here are the top co-authors by number of shared publications:
Monica M. Dua
Section of Hepatobiliary & Pancreatic Surgery, Department of Surgery, Stanford University Hospital, Stanford, CA, USA
17 shared publicationsGeorge A. Poultsides
Section of Surgical Oncology, Department of Surgery, Stanford University Hospital, Stanford, CA, USA
14 shared publicationsJeffrey A. Norton
Section of Surgical Oncology, Department of Surgery, Stanford University Hospital, Stanford, CA, USA
13 shared publicationsDavid J. Worhunsky
Department of Surgery, Stanford University School of Medicine, Stanford, CA, USA
10 shared publicationsAmy Y. Li
Section of Hepatobiliary Surgery and Surgical Oncology, Department of Surgery, Stanford University School of Medicine, Stanford, CA, United States
8 shared publications- George A. Poultsides
Department of Surgery, Stanford University, Stanford, CA, USA
6 shared publications
Latest Publications
- 5 May 2026
- Published by Elsevier in Journal of Surgical Education
- Vol. 83 (7) , 103967
Turning Ideas into Teaching Tools: How We Create Our Educational Surgical Videos
- 5 May 2026
- Published by Elsevier in Journal of Surgical Education
- Vol. 83 (7) , 103967
Turning Ideas into Teaching Tools: How We Create Our Educational Surgical Videos
- Open Access
- 1 March 2026
- Published by AME Publishing Company in Gland Surgery
- Vol. 15 (3) , 58
Robotic converts: does everyone see the light?
Robotic converts: does everyone see the light?
- 1 March 2026
- Published by AME Publishing Company in Gland Surgery
- Vol. 15 (3) , 58
Open AccessRobotic converts: does everyone see the light?
Robotic converts: does everyone see the light?
- Open Access
- 1 November 2025
- Published by AME Publishing Company in Journal of Visualized Surgery
- Vol. 11, 29
Combined robotic cholecystoduodenal fistula repair and hepaticoduodenostomy with bile duct exploration in a patient with recurrent choledocholithiasis and prior Bouveret syndrome: a case report
Background: Cholecystoenteric fistula (CEF) is a rare complication of gallstone disease. The most common type is cholecystoduodenal fistula (CDF). Preoperative diagnosis has historically been challenging, but advances in imaging have improved detection rates. While open repair of CDF is considered the standard operative approach, the use of minimally invasive techniques, either laparoscopic or robotic approaches, has steadily increased. Case Description: We report the case of a 71-year-old woman with a CDF secondary to a previous subtotal fenestrated cholecystectomy. The condition was further complicated by recurrent choledocholithiasis (RC). Both conditions were managed in a single-stage robotic procedure, including a completion cholecystectomy, bile duct exploration, removal of the biliary calculi, and end-to-side hepaticoduodenostomy over the CDF duodenal defect. To our knowledge, this is the first reported case in which both conditions were addressed simultaneously using a biliary bypass on a robotic platform. At the 3-month follow-up, the patient had complete resolution of symptoms, supporting the compatibility of our approach with the existing literature on robotic management of CDF and RC. Conclusions: Given the intrinsic benefits of the robotic approach and growing body of supporting evidence, we report the feasibility of this approach in the management of CDF and RC.
- 1 November 2025
- Published by AME Publishing Company in Journal of Visualized Surgery
- Vol. 11, 29
Open AccessCombined robotic cholecystoduodenal fistula repair and hepaticoduodenostomy with bile duct exploration in a patient with recurrent choledocholithiasis and prior Bouveret syndrome: a case report
Background: Cholecystoenteric fistula (CEF) is a rare complication of gallstone disease. The most common type is cholecystoduodenal fistula (CDF). Preoperative diagnosis has historically been challenging, but advances in imaging have improved detection rates. While open repair of CDF is considered the standard operative approach, the use of minimally invasive techniques, either laparoscopic or robotic approaches, has steadily increased. Case Description: We report the case of a 71-year-old woman with a CDF secondary to a previous subtotal fenestrated cholecystectomy. The condition was further complicated by recurrent choledocholithiasis (RC). Both conditions were managed in a single-stage robotic procedure, including a completion cholecystectomy, bile duct exploration, removal of the biliary calculi, and end-to-side hepaticoduodenostomy over the CDF duodenal defect. To our knowledge, this is the first reported case in which both conditions were addressed simultaneously using a biliary bypass on a robotic platform. At the 3-month follow-up, the patient had complete resolution of symptoms, supporting the compatibility of our approach with the existing literature on robotic management of CDF and RC. Conclusions: Given the intrinsic benefits of the robotic approach and growing body of supporting evidence, we report the feasibility of this approach in the management of CDF and RC.
- 18 October 2025
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 33 (2) , 1536-1537
Robotic Left Hepatectomy with Hilar Dissection and Portal Lymphadenectomy Following Preoperative Gemcitabine, Cisplatin, and Pembrolizumab for Intrahepatic Cholangiocarcinoma
The historic management of resectable intrahepatic cholangiocarcinoma (ICC) included open resection and portal lymphadenectomy.1 In the modern era of effec
- 18 October 2025
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 33 (2) , 1536-1537
Robotic Left Hepatectomy with Hilar Dissection and Portal Lymphadenectomy Following Preoperative Gemcitabine, Cisplatin, and Pembrolizumab for Intrahepatic Cholangiocarcinoma
The historic management of resectable intrahepatic cholangiocarcinoma (ICC) included open resection and portal lymphadenectomy.1 In the modern era of effec
- 20 May 2025
- Published by Wolters Kluwer Health in Pancreas
- Vol. 54 (6) , e505-e506
Not Dead Yet: Managing the Abdominal Catastrophe in Necrotizing Pancreatitis
An abstract is unavailable. This article is available as a PDF only.
- 20 May 2025
- Published by Wolters Kluwer Health in Pancreas
- Vol. 54 (6) , e505-e506
Not Dead Yet: Managing the Abdominal Catastrophe in Necrotizing Pancreatitis
An abstract is unavailable. This article is available as a PDF only.
- 31 March 2025
- Published by Springer Nature
- p. 125-139
Chronic Pancreatitis: Resection
- 16 January 2025
- Published by Elsevier in Journal of Gastrointestinal Surgery
- Vol. 29 (3) , 101962
Association of care fragmentation and hospital cancer designation with survival in gastroesophageal junction cancer: a statewide study
- 16 January 2025
- Published by Elsevier in Journal of Gastrointestinal Surgery
- Vol. 29 (3) , 101962
Association of care fragmentation and hospital cancer designation with survival in gastroesophageal junction cancer: a statewide study
- 15 November 2024
- Published by Wolters Kluwer Health in Journal of the American College of Surgeons
- Vol. 239 (6) , e7-e12
Two-Port Minimally Invasive Nephrolaparoscopic Retroperitoneal Debridement for Pancreatic Necrosis
Walled-off necrosis (WON) occurs in approximately 20% of patients with necrotizing pancreatitis. Infection occurs in approximately 30% of necrosis patients, and despite advances in management, infected necrosis still confers a high mortality between 30 and 40%. While sterile necrosis requires drainage only for cases of symptom relief or “persistent unwellness,” prompt intervention is critical for infected necrosis. Several management strategies exist depending on the location and anatomy of the necrosum. In particular, retroperitoneal collections away from the stomach are typically managed with a step-up approach that begins with percutaneous drain placement. While a minority of patients skirt further intervention, the majority require formal debridement at some point via the existing drain tract. These debridement techniques include video-assisted retroperitoneal debridement (VARD) through a flank incision or minimally invasive retroperitoneal pancreatic (MIRP) necrosectomy under continuous irrigation with a nephroscope. While effective, both debridement strategies have drawbacks: for VARD, the flank incision is prone to infections and hernia while MIRP debridements are tedious and often require repeat operative trips. To overcome these pitfalls, we describe a novel two-trocar minimally invasive hybrid nephro-laparoscopic retroperitoneal debridement technique for an efficient retroperitoneal pancreatic necrosectomy.
- 15 November 2024
- Published by Wolters Kluwer Health in Journal of the American College of Surgeons
- Vol. 239 (6) , e7-e12
Two-Port Minimally Invasive Nephrolaparoscopic Retroperitoneal Debridement for Pancreatic Necrosis
Walled-off necrosis (WON) occurs in approximately 20% of patients with necrotizing pancreatitis. Infection occurs in approximately 30% of necrosis patients, and despite advances in management, infected necrosis still confers a high mortality between 30 and 40%. While sterile necrosis requires drainage only for cases of symptom relief or “persistent unwellness,” prompt intervention is critical for infected necrosis. Several management strategies exist depending on the location and anatomy of the necrosum. In particular, retroperitoneal collections away from the stomach are typically managed with a step-up approach that begins with percutaneous drain placement. While a minority of patients skirt further intervention, the majority require formal debridement at some point via the existing drain tract. These debridement techniques include video-assisted retroperitoneal debridement (VARD) through a flank incision or minimally invasive retroperitoneal pancreatic (MIRP) necrosectomy under continuous irrigation with a nephroscope. While effective, both debridement strategies have drawbacks: for VARD, the flank incision is prone to infections and hernia while MIRP debridements are tedious and often require repeat operative trips. To overcome these pitfalls, we describe a novel two-trocar minimally invasive hybrid nephro-laparoscopic retroperitoneal debridement technique for an efficient retroperitoneal pancreatic necrosectomy.
- Open Access
Distal Pancreatectomy with and without Celiac Axis Resection for Adenocarcinoma: A Comparison in the Era of Neoadjuvant Therapy
Background: Distal pancreatectomy with celiac axis resection (DP-CAR) has been used for selected patients with pancreatic cancer infiltrating the celiac axis. We compared the short- and long-term outcomes between DP-CAR and distal pancreatectomy alone (DP) in patients receiving neoadjuvant therapy. Methods: Patients undergoing DP-CAR from 2013 to 2022 were retrospectively reviewed. Clinicopathologic features, post-operative morbidity, and survival outcomes were compared with patients undergoing DP after neoadjuvant chemotherapy. Results: Twenty-two DP-CAR and thirty-four DP patients who underwent neoadjuvant chemotherapy were identified. There were no differences in comorbidities or CA19-9 levels. OR time was longer for DP-CAR (304 vs. 240 min, p = 0.007), but there was no difference in the transfusion rate (22.7% vs. 14.7%). Vascular reconstruction was more common in DP-CAR (18.2% vs. 0% arterial, p = 0.05; 40.9% vs. 12.5% venous, p = 0.04). There was no difference in morbidity or mortality between the two groups. Although there was a trend towards larger tumors in DP-CAR (5.1 cm vs. 3.8 cm, p = 0.057), the overall survival from the initiation of treatment (32 vs. 28 months, p = 0.43) and surgery (30 vs. 24 months, p = 0.43) were similar. Discussion: DP-CAR is associated with similar survival and morbidity compared to DP patients requiring neoadjuvant chemotherapy and should be pursued in appropriately selected patients.
Open AccessDistal Pancreatectomy with and without Celiac Axis Resection for Adenocarcinoma: A Comparison in the Era of Neoadjuvant Therapy
Background: Distal pancreatectomy with celiac axis resection (DP-CAR) has been used for selected patients with pancreatic cancer infiltrating the celiac axis. We compared the short- and long-term outcomes between DP-CAR and distal pancreatectomy alone (DP) in patients receiving neoadjuvant therapy. Methods: Patients undergoing DP-CAR from 2013 to 2022 were retrospectively reviewed. Clinicopathologic features, post-operative morbidity, and survival outcomes were compared with patients undergoing DP after neoadjuvant chemotherapy. Results: Twenty-two DP-CAR and thirty-four DP patients who underwent neoadjuvant chemotherapy were identified. There were no differences in comorbidities or CA19-9 levels. OR time was longer for DP-CAR (304 vs. 240 min, p = 0.007), but there was no difference in the transfusion rate (22.7% vs. 14.7%). Vascular reconstruction was more common in DP-CAR (18.2% vs. 0% arterial, p = 0.05; 40.9% vs. 12.5% venous, p = 0.04). There was no difference in morbidity or mortality between the two groups. Although there was a trend towards larger tumors in DP-CAR (5.1 cm vs. 3.8 cm, p = 0.057), the overall survival from the initiation of treatment (32 vs. 28 months, p = 0.43) and surgery (30 vs. 24 months, p = 0.43) were similar. Discussion: DP-CAR is associated with similar survival and morbidity compared to DP patients requiring neoadjuvant chemotherapy and should be pursued in appropriately selected patients.
- 4 October 2024
- Published by Elsevier in Surgical Oncology
- Vol. 57, 102153
Predictors of malignant transformation in mucinous pancreatic cystic neoplasm: A systemic review and meta-analysis
- 4 October 2024
- Published by Elsevier in Surgical Oncology
- Vol. 57, 102153
Predictors of malignant transformation in mucinous pancreatic cystic neoplasm: A systemic review and meta-analysis